Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
37 employees
US-based Cygnal Therapeutics develops exoneural drugs for cancer and regenerative diseases.
HQ
Founded
2016
Cygnal Therapeutics, based in Cambridge, United States, focuses on developing exoneural drugs for cancer, immunological, and regenerative diseases. The company aims to revolutionize treatment by targeting the exoneural pathways, offering innovative solutions to improve patient outcomes in these critical areas.
Cygnal Therapeutics has made significant strides in the pharmaceutical industry, contributing to advancements in exoneural drug development. Their pioneering work has positioned them as a key player in the field, impacting the treatment landscape for cancer and regenerative diseases.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Pharmaceuticals, Drugs
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Cygnal Therapeutics founded?
Cygnal Therapeutics was founded in 2016.
Where is Cygnal Therapeutics's headquarters located?
Cygnal Therapeutics's headquarters is located in Cambridge, MA, US.
When was Cygnal Therapeutics's last funding round?
Cygnal Therapeutics's most recent funding round was for $65M (USD) in October 2019.
How many employees does Cygnal Therapeutics have?
Cygnal Therapeutics has 37 employees as of Feb 4, 2024.
How much has Cygnal Therapeutics raised to-date?
As of July 05, 2023, Cygnal Therapeutics has raised a total of $65M (USD) since Oct 8, 2019.
Add Comparison
Total Raised to Date
$65M
USD
Last Update Oct 8, 2019
Last Deal Details
$65M
USD
Oct 8, 2019
Series Unknown
Current Employees
37
Last updated: Feb 4, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts